en · de · es · fr · pt
aod-9604-notes.peptides3081.com › Info › Handling, Analysis, And Quality Control — Practical Notes

Handling, Analysis, And Quality Control — Practical Notes

By Editorial Desk · published 2026-05-23 · last reviewed 2026-06-29 · Info

A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-06-29 and is reviewed periodically as new material appears.

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

Identity and Molecular Context

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

Aod-9604 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized form; visual inspection
SolubilitySoluble in water and aqueous buffersDepends on pH, purity, and counterion
Typical storage-20 °C or below, desiccatedProtect from light; avoid repeated freeze-thaw after reconstitution
Common analytical methodReversed-phase HPLC and mass spectrometryPurity by HPLC; identity and mass by LC-MS or MALDI-TOF
Common synonymshGH fragment 176–191; AOD-9604Names vary in research and product labeling

Regulation and Detection Context

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Related pages on this site

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Further detail

According to the Romania's National Institute of Statistics (INS), Romania's total road network was estimated in 2015 at 86,080 kilometres (53,488 mi). The World Bank estimates the railway network at 22,298 kilometres (13,855 mi) of track, the fourth-largest railway network in Europe. Romania's rail transport experienced a dramatic decline after 1989 and was estimated at 99 million passenger journeys in 2004, but has experienced a recent (2013) revival due to infrastructure improvements and partial privatisation of lines, accounting for 45% of all passenger and freight movements in the country. Bucharest Metro, the only underground railway system, was opened in 1979 and measures 80.01 km (49.72 mi) with an average ridership in 2021 of 720,000 passengers during the workweek in the country. There are sixteen international commercial airports in service today. Over 12.8 million passengers flew through Bucharest's Henri Coandă International Airport in 2017. Romania is a net exporter of electrical energy and is 52nd worldwide in terms of consumption of electric energy. Around a third of the produced energy comes from renewable sources, mostly as hydroelectric power. It has one of the largest refining capacities in Eastern Europe, even though oil and natural gas production has been decreasing for more than a decade. With one of the largest reserves of crude oil and shale gas in Europe it is among the most energy-independent countries in the EU, and is looking to expand its nuclear power plant at Cernavodă further.

== Pathogenesis == It is unclear precisely how statins lead to statin-associated autoimmune myopathy. The disorder is positively associated with HLA-DR11 and the DRB1*11:01 allele. There are likely other unidentified genetic and environmental risk factors associated with SAAM, given the prevalence of the DRB1 allele and the low incidence of autoimmunity in that group. Statins inhibit HMG-CoA reductase activity and consequently lower cholesterol levels in the blood. However, by doing this, they also increase the production of the HMG-CoA reductase protein. SAAM hypothetically triggers this increase in the production of HMG-CoA reductase and associated abnormal processing of this protein in genetically susceptible individuals. This abnormal processing theoretically triggers the generation of antibodies targeting the HMG-CoA reductase protein resulting in SAAM. Another theory postulates that the configuration of the HMG-CoA reductase protein may change when statin medications bind to it causing the protein to expose certain antigens that the immune system is not tolerant to resulting in the production of antibodies against it.

The electricity production in Colombia comes mainly from Renewable energy sources. 69.93% is obtained from the hydroelectric generation. Colombia's commitment to renewable energy was recognized in the 2014 Global Green Economy Index (GGEI), ranking among the top 10 nations in the world in terms of greening efficiency sectors.

Eicosanoids, retinoids, oestrogens, melanocyte-stimulating hormone, endothelins, psoralens, hydantoin, forskolin, cholera toxin, isobutylmethylxanthine, diacylglycerol analogues, and UV irradiation all trigger melanogenesis and, in turn, pigmentation.

Sources: en.wikipedia.org

Supporting material

Kissinger, who accompanied Nixon to China, spent much time talking to the suave Chinese Premier Zhou Enlai about Vietnam, pressing him to end the supply of arms to North Vietnam. The talks went nowhere as Zhou told Kissinger that the North Vietnamese played off China against the Soviet Union, and to cut off North Vietnam would allow it to fall into the Soviet sphere of influence. As the Chinese People's Liberation Army had been badly bloodied by the Red Army in a border war in 1969, Zhou stated that to face a two-front war with Chinese forces facing North Vietnam in the south and the Soviet Union in the north was not acceptable to his government. Zhou offered Kissinger only the vague message that China supported efforts to find peace in Vietnam while refusing to make any promises, though Kissinger also noted that Zhou declined to endorse North Vietnam's demands. Despite Nixon's coming visit, in late 1971, the Chinese drastically increased their military aid to North Vietnam and continued to send a massive amount of weapons south even as Nixon and Kissinger exchanged pleasantries with Mao and Zhou in Beijing. As usual, when the Chinese increased their supply of arms to North Vietnam, the Soviet Union did likewise, as both Communist states competed with one another for influence in Hanoi by trying to be the biggest supplier of weapons. On 30 March 1972, the PAVN launched the Easter Offensive that overran several provinces in South Vietnam while pushing the ARVN to the brink of collapse. By 1 April 1972, the 3rd ARVN division was retreating south with their families.

== In cancer progression and metastasis == Initiation of metastasis requires invasion, which is enabled by EMT. Carcinoma cells in a primary tumor lose cell-cell adhesion mediated by E-cadherin repression and break through the basement membrane with increased invasive properties, and enter the bloodstream through intravasation. Later, when these circulating tumor cells (CTCs) exit the bloodstream to form micro-metastases, they undergo MET for clonal outgrowth at these metastatic sites. Thus, EMT and MET form the initiation and completion of the invasion-metastasis cascade. At this new metastatic site, the tumor may undergo other processes to optimize growth. For example, EMT has been associated with PD-L1 expression, particularly in lung cancer. Increased levels of PD-L1 suppresses the immune system which allows the cancer to spread more easily. EMT confers resistance to oncogene-induced premature senescence. Twist1 and Twist2, as well as ZEB1 protects human cells and mouse embryonic fibroblasts from senescence. Similarly, TGF-β can promote tumor invasion and evasion of immune surveillance at advanced stages. When TGF-β acts on activated Ras-expressing mammary epithelial cells, EMT is favored and apoptosis is inhibited. This effect can be reversed by inducers of epithelial differentiation, such as GATA-3. EMT has been shown to be induced by androgen deprivation therapy in metastatic prostate cancer. Activation of EMT programs via inhibition of the androgen axis provides a mechanism by which tumor cells can adapt to promote disease recurrence and progression.

In the case of chain-end scission, monomers are released and this process is referred to as unzipping or depolymerization. Which mechanism dominates will depend on the type of polymer and temperature; in general, polymers with no or a single small substituent in the repeat unit will decompose via random-chain scission. The sorting of polymer waste for recycling purposes may be facilitated by the use of the resin identification codes developed by the Society of the Plastics Industry to identify the type of plastic.

=== Morphological instabilities === In an ideal world, the spatial concentration of particles within the SSZ would remain constant throughout solidification. As it happens, though, the concentration of particles does change during compression, and this process is highly sensitive to solidification speed. At low freezing rates, Brownian motion takes place, allowing particles to move easily away from the solid-liquid interface and maintain a homogeneous suspension. In this situation, the suspension is always warmer than the solidified portion. At fast solidification speeds, approaching VC, the concentration, and concentration gradient at the solid-liquid interface increases because particles cannot redistribute soon enough. When it has built up enough, the freezing point of the suspension is below the temperature gradient in the solution and morphological instabilities can occur. For situations where the particle concentration bleeds into the diffusion layer, both the actual and freezing temperature dip below the equilibrium freezing temperature creating an unstable system. Often, these situations lead to the formation of what are known as ice lenses. These morphological instabilities can trap particles, preventing full redistribution and resulting in inhomogeneous distribution of solids along the freezing direction as well as discontinuities in the ceramic walls, creating voids larger than intrinsic pores within the walls of the porous ceramic.

=== Post-operative changes === One cause of Type 1 diabetes is through surgery. This is due to the destruction or intentional removal of a portion of or the entire pancreas. This decreases the number of beta-islet cells capable of producing insulin greatly, resulting in an acquired form of Type 1 diabetes known as pancreatogenic diabetes mellitus. This type of diabetes is most often seen in patients that undergo a pancreatoduodenectomy (a.k.a. Whipple procedure) or a total pancreatectomy. Patients who undergo a total pancreatectomy are medically recognized as having type 3c diabetes. This nomenclature informs medical professionals that the patient has no insulin production and requires extensive monitoring to avoid severe hyperglycemia or hypoglycemia. Hypoglycemia is significantly more worrying in these patients due to the potential for coma and even death, as hyperglycemia causes more subtle damage over a longer period of time and only affects consciousness at severe levels. Following these surgeries, patients may have reduced levels of insulin; they may also have reduced levels of glucagon, a hormone that raises blood sugar. Many of these patients require an insulin pump that constantly injects insulin to reduce their sugar levels .

Sources: en.wikipedia.org

Frequently asked questions

How is AOD9604 typically stored?

Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.

What methods confirm AOD9604 identity?

Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.

Is AOD9604 the same as human growth hormone?

No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

Network